

NOVACYT

Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Launch of new animal multiplex assays at London Vet Show

Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs

Paris, France, Eastleigh and Manchester, UK - 14 November 2024 -Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it is launching two new assays for gastrointestinal disease in dogs and cats at the London Vet Show, held from 14-15 November 2024.

The genesig® PLEX kits for Canine and Feline Gastrointestinal (GI) Diseases are multiplexed qPCR assays that detect six disease-causing pathogens in the digestive system of cats and dogs in a two-tube assay, delivering a streamlined and efficient testing solution for centralised veterinary laboratories. Each target has been carefully selected to detect a key pathogen that can cause potentially serious or life-threatening GI illnesses in cats and dogs.

Testing for six pathogens using one sample will reduce hands-on time for laboratory technicians as well as the use of consumables. The kits provide results in less than three hours, enabling quicker, more comprehensive results to the veterinarian and ensuring faster treatment for the family pet.

If you are attending the London Vet Show and would like further information on the new genesig® PLEX kits for Canine and Feline Gastrointestinal (GI) Diseases, or Novacyt's wider portfolio of veterinary assays, the Novacyt team can be found at Booth No A49.

Lyn Rees, CEO of Novacyt, said: *"Following consultation with our customers and further market research, we saw clear demand in the veterinary industry for multiplex assays that target several companion animal pathogens using a single sample. With the launch of our two new genesig® PLEX kits for cats and dogs, we are making testing for these gastrointestinal pathogens more cost-effective, faster and less hands-on for laboratories, and enabling quicker results for veterinarians."*

"Adding to the 200+ veterinary assays in Primer Design's existing portfolio, these tests demonstrate our continued commitment to identifying emerging diagnostic needs and providing best-in-class solutions for our customers."

Contacts

Novacyt SA

Lyn Rees, Chief Executive Officer
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Michael Palser

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com /
y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Paul McManus / Lianne Applegarth
Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

+44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures and commercialises a range of molecular assays and instrumentation to deliver workflows and

manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

- | | |
|--------------------------|---|
| Clinical | Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas: <ul style="list-style-type: none">• Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests• Precision Medicine: DPYD genotyping assay• Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel |
| Instrumentation | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: <ul style="list-style-type: none">• Ranger® Technology: automated DNA sample preparation and target enrichment technology• genesig q16 and q32 real-time quantitative PCR (qPCR) instruments |
| Research Use Only | Range of services for the life sciences industry: <ul style="list-style-type: none">• Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry• Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

About the London Vet Show

The London Vet Show is Europe's largest veterinary conference and exhibition. Run with education partners the Royal Veterinary College and British Veterinary Association, the London Vet Show brings together thousands of veterinary professionals, innovators and industry giants, with over 400 exhibitors and 200 speakers.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAQKNBPABDDKDD